News

Month Year

Month Year

Aruvant to Participate in Numerous Scientific and Investor Conferences in February and March

Feb 11, 2021
Aruvant Announces the European Medicines Agency (EMA) Granted Priority Medicines (PRIME) Designation to ARU-1801 for the Treatment of Sickle Cell Disease

Feb 3, 2021
Aruvant Chooses Lonza to Manufacture ARU-1801, a Potentially Curative Treatment for Sickle Cell Disease, for Pivotal Trial

Jan 18, 2021
Aruvant's Data Presented in Oral Presentation at the 62nd American Society of Hematology (ASH) Annual Meeting Demonstrates Promise of ARU-1801 as a Potentially Curative Treatment for Sickle Cell Disease

Dec 7, 2020

--Data from improved manufacturing process resulted in significantly improved ARU-1801 product profile--
Aruvant to Participate in SVB Leerink's Biopharma Private Company Connect December 15 to 17

Dec 1, 2020

Show per page